company background image
TGTX

TG Therapeutics NasdaqCM:TGTX Stock Report

Last Price

US$6.00

Market Cap

US$811.6m

7D

7.5%

1Y

-81.4%

Updated

03 Oct, 2022

Data

Company Financials +
TGTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TGTX Stock Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

TG Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TG Therapeutics
Historical stock prices
Current Share PriceUS$6.00
52 Week HighUS$35.94
52 Week LowUS$3.48
Beta2.18
1 Month Change-11.77%
3 Month Change14.29%
1 Year Change-81.37%
3 Year Change15.16%
5 Year Change-49.58%
Change since IPO428.05%

Recent News & Updates

Sep 21

TG Therapeutics: We Are Just Hanging In There

Summary 2022 has been a terrible year for a once-promising TGTX. Maybe the FDA decision on December 28 will help us break even. I don't have any further expectations from TGTX. TG Therapeutics, Inc. (TGTX) is an unfortunate story for investors. Just like with Amarin Corporation plc (AMRN), the investment logic here was sound, however, it was ruined by random events. In Amarin's case, we had one approval, one major label expansion, and then along came Judge Du. In TG's case, we had one small approval, one major new approval on the horizon, and then they were forced to withdraw the first drug from the market. This killed the buzz around the upcoming approval, which, as we always knew, was the big thing. So the stock has ridden itself all the way down to $6, and nothing seems to be able to move it. December 28 is the big day, when the FDA will decide on the NDA of ublituximab in multiple sclerosis. There are numerous reasons why we think this will turn out well; and a few reasons it might not. I gave some stats in an earlier article. The Ultimate trials were run under an agreement with the FDA called the Special Protocol Assessment, which means, essentially, that the FDA agrees to the "scientificality" of the clinical endpoints chosen by the company. So if a trial under an SPA met the clinical endpoint - which it did here - the FDA is bound to approve. In about 1000 such SPAs since 1997, the FDA has rescinded its agreement on just 1% of the time. So there's a 99% chance of approval. That's one big reason for our optimism. Ublituximab has consistently scored below 0.1 for the Annualized Relapse Rate or ARR, a feat that none of the other currently approved drugs - not a single one - has been able to achieve in their pivotal trials. ARR is an important metric for calculating drug efficacy in MS trials. It is defined as the number of relapses of MS occurring during a one-year period. Ublituximab not only beat the comparator drug in the Ultimate trials, but it also beat Roche's (RHHBY) Ocrevus or ocrelizumab, a blockbuster MS drug, on a cross trial basis. I discussed the 1-hour infusion time earlier. While the company in its earnings call states that this is the foremost differentiator, I am not sure I can agree. Ocrevus has had a 2-hour infusion program approved in December 2020, and given the infusion-related AEs seen in Ultimate, I believe not just the infusion time but also the hospital setting itself matters a lot. I think the company needs to focus on other differentiating factors. In an earlier article, I wondered whether the Unity-CLL trial will need to be re-analyzed for ublituximab's contribution to the poor OS data. However, I think that's kind of moot. Ubli's central adverse effect is infection, which occurs because it kills B-cells, like it is supposed to. In the Ultimate trials, there were three deaths, all infection related. However, in Unity, infection was not the issue, at least not the issue that led to the poor OS. Umbralisib has its own P13K-related issues. So I doubt ublituximab will have a problem here, and if this was the cause for the 3-month delay in review. About this delay, in their latest earnings call, the company provided some color: Since this submission, as is customary during a BLA review process, we have continued to respond to additional FDA information requests, none to my knowledge, specifically related to the submission that resulted in the delay. Generally speaking, my team tells me that they believe the process is moving forward as expected.

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Aug 25

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

TG Therapeutics (NASDAQ:TGTX) on Thursday said results from its two-part phase 3 trials evaluating its investigational monoclonal antibody ublituximab for the treatment of multiple sclerosis were published in the peer-reviewed New England Journal of Medicine (NEJM). TGTX stock +0.5% to $7.52 in morning trading. Ublituximab, a targeted B-cell therapy, showed significant reductions in risk of relapses, as well as reduction of active or new brain lesions, in the two-part late-stage trial, called ULTIMATE I and II. If approved, the therapy would be given as a 1-hour infusion every 6 months, following the first dose. The U.S. FDA and Europe's drug regulator are currently reviewing marketing applications for ublituximab for the treatment of relapsing forms of multiple sclerosis in adults. The FDA is set to decide on the application by Dec. 28, 2022, TG Therapeutics (TGTX) had previously said.

Shareholder Returns

TGTXUS BiotechsUS Market
7D7.5%3.9%1.0%
1Y-81.4%-22.7%-20.0%

Return vs Industry: TGTX underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: TGTX underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is TGTX's price volatile compared to industry and market?
TGTX volatility
TGTX Average Weekly Movement15.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: TGTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: TGTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1993173Mike Weisshttps://www.tgtherapeutics.com

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

TG Therapeutics Fundamentals Summary

How do TG Therapeutics's earnings and revenue compare to its market cap?
TGTX fundamental statistics
Market CapUS$811.62m
Earnings (TTM)-US$288.50m
Revenue (TTM)US$6.96m

116.6x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TGTX income statement (TTM)
RevenueUS$6.96m
Cost of RevenueUS$762.00k
Gross ProfitUS$6.20m
Other ExpensesUS$294.70m
Earnings-US$288.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.13
Gross Margin89.05%
Net Profit Margin-4,144.51%
Debt/Equity Ratio53.5%

How did TGTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is TGTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TGTX?

Other financial metrics that can be useful for relative valuation.

TGTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue100x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does TGTX's PB Ratio compare to its peers?

TGTX PB Ratio vs Peers
The above table shows the PB ratio for TGTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.5x
ALEC Alector
2.7x-29.1%US$769.5m
MIRM Mirum Pharmaceuticals
7.2x78.7%US$794.4m
QURE uniQure
1.9x38.5%US$912.6m
KNSA Kiniksa Pharmaceuticals
6.1x12.3%US$933.7m
TGTX TG Therapeutics
6.3x52.9%US$811.6m

Price-To-Book vs Peers: TGTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the peer average (4.5x).


Price to Earnings Ratio vs Industry

How does TGTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: TGTX is expensive based on its Price-To-Book Ratio (6.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is TGTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TGTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TGTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TGTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TGTX ($6) is trading below our estimate of fair value ($186.19)

Significantly Below Fair Value: TGTX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is TG Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


52.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TGTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TGTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TGTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TGTX's revenue (63.1% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: TGTX's revenue (63.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TGTX is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has TG Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-23.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TGTX is currently unprofitable.

Growing Profit Margin: TGTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TGTX is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.

Accelerating Growth: Unable to compare TGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: TGTX has a negative Return on Equity (-223.58%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is TG Therapeutics's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TGTX's short term assets ($202.6M) exceed its short term liabilities ($43.3M).

Long Term Liabilities: TGTX's short term assets ($202.6M) exceed its long term liabilities ($79.3M).


Debt to Equity History and Analysis

Debt Level: TGTX has more cash than its total debt.

Reducing Debt: TGTX's debt to equity ratio has increased from 0.2% to 53.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TGTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TGTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is TG Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

TG Therapeutics Dividend Yield vs Market
How does TG Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (TG Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (TG Therapeutics)0%

Notable Dividend: Unable to evaluate TGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TGTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TGTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TGTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.6yrs

Average management tenure


CEO

Mike Weiss (56 yo)

10.83yrs

Tenure

US$42,666,831

Compensation

Mr. Michael S. Weiss, Esq., J.D., also known as Mike, has been an Executive Chairman of Mustang Bio Inc. since January 2017 and served as the Interim President and Chief Executive Officer at Mustang Bio In...


CEO Compensation Analysis

Mike Weiss's Compensation vs TG Therapeutics Earnings
How has Mike Weiss's remuneration changed compared to TG Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$288m

Mar 31 2022n/an/a

-US$326m

Dec 31 2021US$43mUS$1m

-US$348m

Sep 30 2021n/an/a

-US$343m

Jun 30 2021n/an/a

-US$345m

Mar 31 2021n/an/a

-US$319m

Dec 31 2020US$32mUS$1m

-US$279m

Sep 30 2020n/an/a

-US$231m

Jun 30 2020n/an/a

-US$206m

Mar 31 2020n/an/a

-US$189m

Dec 31 2019US$13mUS$637k

-US$173m

Sep 30 2019n/an/a

-US$187m

Jun 30 2019n/an/a

-US$159m

Mar 31 2019n/an/a

-US$167m

Dec 31 2018US$14mUS$656k

-US$173m

Sep 30 2018n/an/a

-US$150m

Jun 30 2018n/an/a

-US$148m

Mar 31 2018n/an/a

-US$132m

Dec 31 2017US$10mUS$525k

-US$118m

Sep 30 2017n/an/a

-US$111m

Jun 30 2017n/an/a

-US$105m

Mar 31 2017n/an/a

-US$92m

Dec 31 2016US$4mUS$375k

-US$78m

Sep 30 2016n/an/a

-US$72m

Jun 30 2016n/an/a

-US$61m

Mar 31 2016n/an/a

-US$62m

Dec 31 2015US$14mUS$325k

-US$63m

Compensation vs Market: Mike's total compensation ($USD42.67M) is above average for companies of similar size in the US market ($USD4.14M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TGTX's management team is seasoned and experienced (7.6 years average tenure).


Board Members

Experienced Board: TGTX's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:TGTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Jan 22SellUS$1,282,527Michael WeissIndividual68,220US$19.20
05 Jan 22SellUS$1,622,737Sean PowerIndividual84,965US$19.20

Ownership Breakdown

What is the ownership structure of TGTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders7,264,7275.4%
General Public15,568,40911.5%
Institutions112,436,08783.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.


Top Shareholders

Top 25 shareholders own 73.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.52%
State Street Global Advisors, Inc.
14,235,263$85.4m47.84%no data
9.63%
The Vanguard Group, Inc.
13,020,832$78.1m7.34%no data
6.85%
BlackRock, Inc.
9,262,325$55.6m3.66%no data
5.95%
FMR LLC
8,054,406$48.3m-60.38%no data
4.99%
Maverick Capital, Ltd.
6,747,549$40.5m1.05%0.94%
4.15%
Michael Weiss
5,614,011$33.7m-8.18%no data
3.67%
Millennium Management LLC
4,958,552$29.8m127.81%0.04%
3.6%
Opus Point Partners
4,874,010$29.2m0%100%
3.1%
Wellington Management Group LLP
4,187,444$25.1m4.15%no data
2.44%
683 Capital Management, LLC
3,300,000$19.8m26.98%1.44%
1.98%
Deerfield Management Company, L.P. Series C
2,677,500$16.1m0%0.5%
1.72%
Geode Capital Management, LLC
2,323,604$13.9m6.17%no data
1.65%
Federated Hermes, Inc.
2,234,979$13.4m185.61%0.04%
1.54%
Assenagon Asset Management S.A.
2,088,952$12.5m722.33%0.04%
1.45%
Paradigm Biocapital Advisors LP
1,964,709$11.8m0%2.22%
1.35%
Morgan Stanley, Investment Banking and Brokerage Investments
1,831,974$11.0m69.2%no data
1.27%
Citadel Advisors LLC
1,717,444$10.3m59.48%0.02%
1.1%
Alkeon Capital Management, LLC
1,484,398$8.9m-2.04%0.08%
1.07%
Two Sigma Investments, LP
1,448,330$8.7m75.39%0.03%
0.92%
Northern Trust Global Investments
1,244,889$7.5m-0.63%no data
0.91%
Norges Bank Investment Management
1,229,777$7.4m0%no data
0.9%
D. E. Shaw & Co., L.P.
1,213,778$7.3m348.96%0.01%
0.87%
Renaissance Technologies LLC
1,181,100$7.1m497.72%0.01%
0.81%
Group One Trading LP, Asset Management Arm
1,096,369$6.6m-39.74%0.2%
0.7%
Pura Vida Investments, LLC
950,813$5.7m189.72%0.84%

Company Information

TG Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: TG Therapeutics, Inc.
  • Ticker: TGTX
  • Exchange: NasdaqCM
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$811.615m
  • Shares outstanding: 135.27m
  • Website: https://www.tgtherapeutics.com

Number of Employees


Location

  • TG Therapeutics, Inc.
  • 2 Gansevoort Street
  • 9th Floor
  • New York
  • New York
  • 10014
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TGTXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2011
NKB2DB (Deutsche Boerse AG)YesCommon StockDEEURDec 2011
0VGILSE (London Stock Exchange)YesCommon StockGBUSDDec 2011

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.